Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?

详细信息    查看全文

• 作者：Erica Tsang ; Heather A. Leitch
• 关键词：Ferritin ; Iron overload ; Myelodysplastic syndromes ; MDS ; Erythropoiesis ; stimulating agents ; ESA
• 刊名：Annals of Hematology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：95
• 期：1
• 页码：73-78
• 全文大小：386 KB
• 参考文献：1.Steensma DP, Bennett JM (2006) The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 81(1):104–130PubMed CrossRef
  2.Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079–2088PubMed
  3.Schiffer CA (2006) Clinical issues in the management of patients with myelodysplasia. Hematology Am Soc Hematol Educ Program. 205–10.
  4.Ganz T (2006) Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 507:29–35CrossRef
  5.De Swart L, Smith A, Fenaux P, Bowen D, Sanz G, Hellstrom-Lindberg E et al (2011) Transfusion-dependency is the most important prognostic factor for survival in 1000 newly diagnosed MDS patients with low- and intermediate-1 risk MDS in the European LeukemiaNet MDS Registry. Blood 118(21):1195–1196
  6.de Swart L, Smith A, Fenaux P, Symconidis A, Hellstrom-Lindberg E, Sanz G et al (2010) Disease-management of low- and intermediate-1 risk myelodysplastic syndromes: report on 800 newly diagnosed MDS patients from the European LeukemiaNet MDS Registry. Blood 116(21):1201–2a
  7.Malcovati L, Della Porta MG, Cazzola M (2006) Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91(12):1588–1590PubMed
  8.Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23(30):7594–7603PubMed CrossRef
  9.Sanz G, Nomdedeu B, Such E, Bernal T, Belkaid M, Ardanaz T et al (2008) Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 112(11):238–9a
  10.Hellstrom-Lindberg E, Birgegard G, Lockner D, Helmers C, Ost A, Wide L (1991) Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol 47(5):355–360CrossRef
  11.Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I et al (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120(6):1037–1046PubMed CrossRef
  12.Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM et al (2008) Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26(21):3607–3613PubMed CrossRef
  13.Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Vassilief D et al (2007) Has treatment with EPO+/− G-CSF an impact on progression to AML and survival in low/int-1-risk MDS? A comparison between French-EPO patients and the IMRAW database. Haematologica 92(S1):158
  14.Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108(2):419–425PubMed CrossRef
  15.Vardiman JW (2010) The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 184(1–2):16–20PubMed CrossRef
  16.Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33(4):451–458PubMed CrossRef
  17.Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM et al (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92(1):68–75PubMed
  18.Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V et al (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111(2):574–582PubMed CrossRef
  19.Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL et al (2010) American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116(20):4045–4059PubMed CrossRef
  20.Mikhael M, Sheftel AD, Ponka P (2010) Ferritin does not donate its iron for haem synthesis in macrophages. Biochem J 429(3):463–471PubMed CrossRef
  21.Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T (2014) 2014. Nat Genet 46(7):678–684PubMed PubMedCentral CrossRef
  22.Ganz T, Nemeth E (2012) Hepcidin and iron homeostasis. Biochim Biophys Acta 1823(9):1434–1443PubMed PubMedCentral CrossRef
  23.Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N et al (2011) Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One 6(8):e23109PubMed PubMedCentral CrossRef
  24.Mossner M, Stohr A, Nolte F, Jann J-C, Fey S, Nowak V et al (2014) Gene expression of the erythroid regulator erythroferrone (ERFE) is highly deregulated in CD71+ erythroprogenitor cells of patients with myelodysplastic syndromes and demonstrates prognostic relevance. Blood 124(21):4620
  
• 作者单位：Erica Tsang (1)
  Heather A. Leitch (2)
  
  1. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
  2. Hematology, St. Paul’s Hospital and the University of British Columbia, 440-1144 Burrard Street, Vancouver, BC, Canada, V6Z 2A5
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

Iron overload (IOL) portends inferior outcome in myelodysplastic syndromes (MDS). Erythropoiesis-stimulating agents (ESA) may reduce red blood cell transfusion requirements. MDS patients receiving ESA were reviewed for characteristics, response to ESA by International Working Group 2006 criteria and ferritin levels. Forty-nine patients received an ESA, had ferritin levels available, and were not receiving iron chelation therapy. Baseline characteristics were not significantly different between ESA responders (ER) and non-responders (ENR; P = NS). The median ESA treatment duration was 6.7 (1.5–85.9) months. Twenty-one (43 %) patients had an ESA response. Median ferritin level in ER was pre-ESA, 473 (range 91–2727) and post-ESA, 801 (130–11,164) ng/mL (P = 0.01), and in ENR pre-ESA, 672 (76–3285) and post-ESA, 1423 (431–6593) ng/mL (P < 0.0001). There was a significant association between ESA response, post-ESA hemoglobin ≥100 g/L, and post-ESA ferritin <1000 ng/mL (P = 0.0003 and 0.03, respectively). At a median follow-up of 28 months, the 2-year overall survival for ER and ENR, respectively, were 80 % and 86 % (P = NS). In lower-risk MDS patients responding to ESA, although an expected decrease in ferritin levels over treatment was not seen, ferritin levels increased less than in non-responders. Whether IOL may be reduced by ESA over a longer treatment duration may require analysis of larger numbers of patients. Keywords Ferritin Iron overload Myelodysplastic syndromes MDS Erythropoiesis-stimulating agents ESA